Autologous Transplantation Is the Strongest Prognostic Factor for Overall Survival in Multiple Myeloma Patients With Deletion 17p: 20-Year Real-World Experience of the Greek Myeloma Study Group

被引：0

作者：

Katodritou, Eirini ^{[1
]}

Kastritis, Efstathios ^{[2
]}

Dalampira, Dimitra ^{[1
]}

Spanoudakis, Emmanouil ^{[3
]}

Pouli, Anastasia ^{[4
]}

Delimpasi, Sosana ^{[5
]}

Sevastoudi, Aggeliki ^{[1
]}

Ntanasis-Stathopoulos, Ioannis ^{[2
]}

Theodorakakou, Foteini ^{[2
]}

Triantafyllou, Theodora ^{[1
]}

Fotiou, Despina ^{[2
]}

Daiou, Aikaterini ^{[1
]}

Koutoukoglou, Prodromos ^{[1
]}

Tsirou, Kyriaki ^{[1
]}

Kyriakidis, Gerasimos ^{[4
]}

Migkou, Magdalini ^{[2
]}

Kyrtsonis, Marie-Christine ^{[6
,7
]}

Kotsopoulou, Maria

Kostopoulos, Ioannis ^{[8
]}

Gavriatopoulou, Maria ^{[2
]}

Verrou, Evgenia ^{[1
]}

Dimopoulos, Meletios ^{[2
]}

Terpos, Evangelos ^{[2
]}

机构：

[1] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Hosp Alexandroupolis, Dept Hematol, Alexandroupolis, Greece

[4] Agios Savvas Canc Hosp, Dept Hematol, Athens, Greece

[5] Gen Hosp Evangelismos, Athens, Greece

[6] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Propaedeut Internal Med 1, Athens, Greece

[7] Metaxa Canc Hosp, Dept Haematol, Piraeus, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Sci, Dept Biol, Flow Cytometry Unit, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-224

引用

页码：S166 / S167

页数：2

共 38 条

[21] Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer: Treatment Pattern and Survival Analysis of a 20-Year Real-World Study
CAO Nida
ZHU Xiaohong
MA Fangqi
XU Yan
DONG Jiahuan
QIN Mengmeng
LIU Tianshu
ZHU Chunchao
GUO Weijian
DING Honghua
GUO Yuanbiao
LIU Likun
SONG Jinjie
WU Jiping
CHENG Yuelei
ZENG Lin
ZHAO Aiguang
Chinese Journal of Integrative Medicine, 2024, (06) : 489 - 498
[22] Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study Treatment pattern and outcomes in patients with multiple myeloma
He, Jianming
Schmerold, Luke
Van Rampelbergh, Rian
Qiu, Lugui
Potluri, Ravi
Dasgupta, Anandaroop
Li, Lin
Li, Yunan
Hu, Peter
Nemat, Sepideh
Smugar, Steven S.
Zeltzer, Paul
Appiani, Carlos
Li, Qing
Mehra, Maneesha
Richarz, Ute
ADVANCES IN THERAPY, 2021, 38 (01) : 640 - 659
[23] p53 deletion yields high response rates but rapid progression and poor overall survival in multiple myeloma patients undergoing autologous stem cell transplantation
Mikhael, Joseph R.
Goodwin, Jodi
Qi, Xiaoying
Xu, Wei
Stewart, Keith
Reece, Donna
Chen, Christine
Trudel, Suzanne
Kukreti, Vishal
Chang, Hong
BLOOD, 2007, 110 (11) : 290A - 290A
[24] p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
Chang, H
Qi, C
Yi, QL
Reece, D
Stewart, AK
BLOOD, 2005, 105 (01) : 358 - 360
[25] Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting
Garrido, David
Slavutsky, Irma
Riva, Eloisa
CURRENT PROBLEMS IN CANCER, 2023, 47 (01)
[26] Real-World Analysis of Characteristics and Main Outcomes of Multiple Myeloma Patients: Impact of Prognostic Scores, Access to Novel Agents and Autologous Stem-Cell Transplantation
Ferreira, Flavia
Lacerda, Marcelo
Figueiredo, Pedro
Zing, Natalia
Araujo, Camila
Reis, Isabel
Nascimento, Anderson
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S239 - S240
[27] "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
Katodritou, Eirini
Vadikolia, Chrysanthi
Lalagianni, Chrysavgi
Kotsopoulou, Maria
Papageorgiou, Georgia
Kyrtsonis, Marie-Christine
Matsouka, Panagiota
Giannakoulas, Nikolaos
Kyriakou, Despoina
Karras, Georgios
Anagnostopoulos, Nikolaos
Michali, Evridiki
Briasoulis, Evangelos
Hatzimichael, Eleftheria
Spanoudakis, Emmanouil
Zikos, Panagiotis
Tsakiridou, Anastasia
Tsionos, Konstantinos
Anargyrou, Konstantinos
Symeonidis, Argiris
Maniatis, Alice
Terpos, Evangelos
ANNALS OF HEMATOLOGY, 2014, 93 (01) : 129 - 139
[28] Prognostic factors and clinical characteristics of patients with newly diagnosed non-secretory multiple myeloma in the era of new drugs in "real-world" study: Experiences of the Polish Myeloma Group
Charlinski, Grzegorz
Szudy-Szczyrek, Aneta
Podgajna, Martyna
Mielnik, Michal
Kopinska, Anna
Tyczynska, Agata
Usnarska-Zubkiewicz, Lidia
Bolkun, Lukasz
Wiater, Elzbieta
Krzystanski, Mateusz
Vesole, David H.
Jurczyszyn, Artur
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024,
[29] “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
Eirini Katodritou
Chrysanthi Vadikolia
Chrysavgi Lalagianni
Maria Kotsopoulou
Georgia Papageorgiou
Marie-Christine Kyrtsonis
Panagiota Matsouka
Nikolaos Giannakoulas
Despoina Kyriakou
Georgios Karras
Nikolaos Anagnostopoulos
Evridiki Michali
Evangelos Briasoulis
Eleftheria Hatzimichael
Emmanouil Spanoudakis
Panagiotis Zikos
Anastasia Tsakiridou
Konstantinos Tsionos
Konstantinos Anargyrou
Argiris Symeonidis
Alice Maniatis
Evangelos Terpos
Annals of Hematology, 2014, 93 : 129 - 139
[30] P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
Qi, XY
Yi, QL
Reece, D
Stewart, AK
Chang, H
BLOOD, 2004, 104 (11) : 303B - 303B

← 1 2 3 4 →